6H-indolo[2,3-b]quinoxalines: DNA and protein interacting scaffold for pharmacological activities

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 10, 2013, Pages 1415-1420

  Hari Narayana Moorthy, N S ^a,b   Manivannan, E ^c   Karthikeyan, C ^b   Trivedi, Piyush ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^c DEVI AHILYA UNIVERSITY   (India)

Author keywords

3 b quinoxalines; 6h indolo 2; Anticancer; Antiviral; Dna intercalation; P glycoprotein

Indexed keywords

(2 METHYL 2 [(6 METHYL 6H INDOLO[2 3 B]QUINOXALINE 4 YL)METHYLAMINO] 1 3 PROPANEDIOL); 1 4 DIBUTOXY 6H INDOLO[2 3 B]QUINOXALINE; 2 3 DIMETHYL 6 (2 DIMETHYL AMINOETHYL) 6H INDOLO[2 3 B]QUINOXALINE AND 6 (2 DIMETHYLAMINOETHYL) 6H INDOLO[2 3 B]QUINOXALINE; 4 7 DIBUTOXY 2 3 DIHYDROBENZIMIDAZOL 2 SPIRO 3 INDOLIN 2 ONE; 6(H) INDOLO [2 3 B]QUINOXALINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; PYRAZINO[2 3 B]INDOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TILORONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DNA BINDING; DRUG STRUCTURE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PARTIAL HEPATECTOMY; RHEUMATOID ARTHRITIS; THERMOSTABILITY;

ANIMALS; DNA; HUMANS; INDOLES; PROTEINS; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881505849     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113139990005     Document Type: Article

References (54)

1. Harmenberg, J.; Wahren, B.; Bergman, J.; Akerfeldt, S.; Lundblad, L. Antiherpesvirus activity and mechanism of action of indolo-(2,3- b)quinoxaline and analogs. Antimicrob. Agents Chemother., 1988, 32(11), 1720-1724.
2. Harmenberg, J.; Akesson-Johansson, A.; Gräslund, A.; Malmfors, T.; Bergman, J.; Wahren, B.; Akerfeldt, S.; Lundblad, L.; Cox, S. The mechanism of action of the anti-herpes virus compound 2,3- dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline. Antiviral Res., 1991, 15, 193-204.
3. Wilhelmsson, L.M.; Kingi, N.; Bergman, J. Interactions of antiviral indolo[2,3-b]quinoxaline derivatives with DNA. J. Med. Chem., 2008, 51, 7744-7750.
4. Goodwin, S.; Smith, A.F.; Horning, E.C. Alkaloids of Ochrosia elliptica Labill. J. Am. Chem. Soc., 1959, 81(8), 1903-1908.
5. Zegar, I.; Graslund, A.; Bergman, J.; Eriksson, M.; Norden, B.; Interaction of ellipticine and an indolo[2,3-b]quinoxaline derivative with DNA and synthetic polynucleotides. Chem. Biol. Interact., 1989, 72, 277-293.
6. Arimondo, P.B.; Baldeyrou, B.; Laine, W.; Bal, C.; Alphonse, F.A.; Routier, S.; Coudert, G.; Merour, J.Y.; Colson, P.; Houssier, C.; Bailly, C. DNA interaction and cytotoxicity of a new series of indolo[2,3-b]quinoxaline and pyridopyrazino[2,3-b]indole derivatives. Chem. Biol. Interact., 2001, 138, 59-75.
7. [Moorthy, N.S.H.N.; Karthikeyan, C.; Trivedi, P. Design, synthesis, cytotoxic evaluation and QSAR study of some 6H-indolo[2,3- b]quinoxaline derivatives. J. Enz. Inhibit. Med. Chem., 2010, 25(3), 394-405.
8. da Silva, J.F.M.; Garden, S.J.; Pinto, A.C. The chemistry of isatins: A review from 1975 to 1999. J. Braz. Chem. Soc., 2001, 12(3), 273-324.
9. Kidani, Y.; Matsuo, M.; Koike, H. Studies on the metal complexes of indoloquinoxaline derivatives II. Spectrophotometric determination of the stability constants of hydroxy indoloquinoxaline metal complexes. Yakugaku Zasshi, 1970, 90, 452-458.
10. Matsuo, M.; Kidani, Y.; Koike, H. Studies on the metal complexes of indoloquinoxaline derivatives III. Metal complexes of 1 and 4- hydroxy indoloquinoxaline. Yakugaku Zasshi, 1970, 90, 601-605.
11. Kidani, Y.; Matsuo, M.; Koike, H. Studies on the metal complexes of indoloquinoxaline derivatives I. Synthesis of hydroxy indoloquinoxaline derivatives. Yakugaku Zasshi, 1970, 90, 54-58.
12. Tyagi, P.; Venkateswararao, A.; Justin Thomas, K.R. Solution processable indoloquinoxaline derivatives containing bulky polyaromatic hydrocarbons: Synthesis, optical spectra, and electroluminescence. J. Org. Chem., 2011, 76, 4571-4581.
13. Schopov, V.; Popov, V. Polyindoloquinoxalines. J. Polymer Sci. Part A-1: Polymer Chem., 2003, 7(7), 1803-1814.
14. Hirata, K.; Araya, J.; Nakaike, S.; Kitamura, K.; Ishida, T. Side chain dependent biding of antitumor indoloquinoxaline derivatives to DNA: comparative spectroscopic and viscometric measurements. Chem. Pharm. Bull., 2001, 49, 44-48.
15. Sehlstedt, U.; Aich, P.; Bergman, J.; Vallberg, H.; Nordean, B.; Graeslund, A. Interactions of the antiviral quinoxaline derivative 9- OH-B220 {2,3-dimethyl-6-(dimethylaminoethyl)- 9-hydroxy-6Hindolo-[ 2,3-b]quinoxaline} with duplex and triplex forms of synthetic DNA and RNA. J. Mol. Biol., 1998, 278, 31-56.
16. Behravan, G.; Leijon, M.; Sehlstedt, U.; Nordean, B.; Vallberg, H.; Bergman, J.; Graslund, A. The interaction of ellipticine derivatives with nucleic acids studied by optical and 1H-NMR spectroscopy: effect of size of the heterocyclic ring system. Biopolymers, 1994, 34, 599-609.
17. Bailly, C.; Ohuigin, C.; Rivalle, C.; Bisagni, E.; Henichart, J.P.; Waring, M.J. Sequence-selective binding of an ellipticine derivative to DNA. Nucl. Acids Res., 1990, 18, 6283-6291.
18. Martínez, R.; Chacón-García, L. The search of DNA-intercalators as antitumoral drugs: What it worked and what did not work. Curr. Med. Chem., 2005, 12, 127-151.
19. Kaczmarek, L.; Peczynaska-Czoch, W.; Osiadacz, J.; Mordarski, M.; Sokalski, W.A.; Boratynaski, J.; Marcinkowska, E.; Glazman- Kusanierczyk, H.; Radzikowski, C. Synthesis, and cytotoxic activity of some novel indolo[2,3-b]quinoline derivatives: DNA topoisomerase II inhibitors. Bioorg. Med. Chem., 1999, 7, 2457-2464.
20. Gago, F. Stacking interactions and intercalative DNA binding. Methods, 1998, 14, 277-292.
21. Reha, D.; Kabelac, M.; Ryjacek, F.; Sponer, J.; Sponer, J.E.; Elstner, M.; Suhai, S.; Hobza, P. Intercalators. 1. Nature of stacking interactions between intercalators (ethidium, daunomycin, ellipticine, and 4′,6-diaminide-2-phenylindole) and DNA base pairs. Ab initio quantum chemical, density functional theory, and empirical potential study. J. Am. Chem. Soc., 2002, 124, 3366-3376.
22. Kostjukov, V.V.; Khomytova, N.M.; Evstigneev, M.P. Partition of thermodynamic energies of drug-DNA complexation. Biopolymers, 2009, 91, 773-790.
23. Shibinskaya, M.O.; Karpenko, A.S.; Lyakhov, S.A.; Andronati, S.A.; Zholobak, N.M.; Spivak, N.Y.; Samochina, N.A.; Shafran, L.M.; Zubritsky, M.J.; Galat, V.F. Synthesis and biological activity of 7H benzo[4,5]indolo[2,3-b]-quinoxaline derivatives. Eur. J. Med. Chem., 2011, 46, 794-798.
24. Karki, S.S.; Hazare, R.; Kumar, S.; Bhadauria, V.S.; Balzarini, J.; de Clercq, E. Synthesis, anticancer and cytostatic activity of some 6H-indolo[2,3-b]quinoxalines. Acta Pharm., 2009, 59, 431-440.
25. Patel, N.; Bergman, J.; Graslund, A. Interaction of the deoxyoligonucleotide duplex d(CGCGATCGCG)2 and anti-hepres virus active indolo[2,3-b]-quinoxaline derivatives. Nucleos. Nucleot. Nucl., 1991, 10, 699-700.
26. Abadi, A.H. 5-Substituted 2-bromoindolo[3,2-b]quinoxalines. A class of potential antitumor agent with cdc25 phosphatase inhibitory properties. Arch. Pharm. Pharm. Med. Chem., 1998, 331, 352-358.
27. Abdel-Sayed, N.I. Novel routes to triazino[5,6-b]indole and indolo[2,3-b]quinoxaline derivatives. Bulgarian Chem. Comm., 2009, 41(4), 362-367.
28. Moorthy, N.S.H.N.; Karthikeyan, C; Trivedi, P. Synthesis, cytotoxic evaluation and in silico pharmacokinetic prediction of some benzo[a]phenazine-5-sulfonic acid derivatives. Med. Chem., 2009, 5(6), 549-557.
29. Moorthy, N.S.H.N.; Karthikeyan, C; Trivedi, P. QSAR studies on cytotoxic acridine 5,7 diones: A comparative study using P_VSA descriptors and topological descriptors. Indian J. Chem., (B), 2007, 46B, 177-184.
30. Moorthy, N.S.H.N.; Trivedi, P. QSAR modelling of some 2- methoxy acridones: Cytotoxic in multi drug resistant cells. Int. J. Cancer Res., 2006, 2(3), 267-276.
31. Kumar, S.R.; Moorthy, N.S.H.N.; Trivedi, P. QSAR studies and molecular shape analysis of azonafide derivatives as topoisomerase II Inhibitors. Indian J. Pharm. Sci., 2003, 65(4), 346-350.
32. Deady, L.W.; Kaye, A.J.; Finlay, G.J.; Baguley, B.C.; Denny, W.A. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl] carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: A new class of putative topoisomerase inhibitors. J. Med. Chem., 1997, 40, 2040-2046.
33. Samata, K.; Yamagishi, T.; Ichihara, T.; Okado, N.; Ikeda, T.; Nakaike, S.; Nagate T. Abstracts of Papers, 56th Annual Meeting of Japan Cancer Association, Kyoto, September 1997, p. 620.
34. Ishida, T.; Mihara, Y.; Hama, Y.; Hanatani, A.; Tarus, M.; Doi, M.; Nakalka, S.; Kitamura, K. Spectroscopic investigation on the intercalation of NCA0424 a potent antitumor indoloquinoxaline derivatives with DNA. Chem. Pharm. Bull., 1998, 46, 739-743.
35. Krueger, R.F.; Mayer, G.D. Tilorone hydrochloride: an orally active antiviral agent. Science, 1970, 169, 1213-1214.
36. Shibinskaya, M.O.; Lyakhov, S.A.; Mazepa, A.V.; Andronati, S.A.; Turov, A.V.; Zholobak, N.M.; Spivak, N.Y. Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6- (2-aminoethyl)-6H-indolo[2,3-b]quinoxalines. Eur. J. Med. Chem., 2010, 45, 1237-1243.
37. Johan, H.; Britta, W.; Jan, B.; Stig, A.; Leif, L. Antiherps virus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogues. Antimicro. Agents Chemother., 1988, 32, 1720-1724.
38. Basley, W.A.; Rees, R.C.; Greager, J.A.; Baldwin, R.W. Antitumour effects of tilorone hydrochloride on the in vivo growth of chemically induced and spontaneously arising rat tumours. Chemother., 1981, 27, 44-52.
39. Stringfellow, D.A.; Glasgow, L.A. Tilorone hydrochloride: an oral interferon-inducing agent. Antimicrob. Agents Chemother., 1972, 2, 73-78.
40. De Clercq, E. Synthetic interferon inducers. Top. Curr. Chem., 1974, 52, 173-208.
41. Lawrence, D.S.; Copper, J.E.; Smith, C.D. Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J. Med. Chem., 2001, 44, 594-601.
42. Lyakhov, S.A.; Litvinova, L.A.; Andronati, S.A.; Berezina, L.K.; Galkin, B.N.; Osetrov, V.E.; Filippova, T.O.; Golovenko, N.Y. Biochemical mechanisms of realization of antiviral and interferoninducing activity of amixine and its analogs. Ukr. Biokhim. Zh., 2001, 4, 108-113.
43. Harbecke, O.; Dahlgren, C.; Bergman, J.; Moller, L. The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo- (2,3-b)quinoxaline inhibits neutrophil production of reactive oxygen species. J. Leukocyte Biol., 1999, 65, 771-777.
44. Loginova, N.S.; Kinzirskii, A.S.; Parshina, O.V.; Mirskaia, E.E.; Ershov, F.I. Effects of interferon inducers on chemically-induced mutagenesis and carcinogenesis. Vestn. Ross. Akad. Med. Nauk, 1996, 3, 28-33.
45. Quesadal, A.R.; Garcia Gratvalos, M.D.; Fernandez Puentes, J.L. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by Pglycoprotein. Br. J. Cancer, 1996, 74, 677-682.
46. Bergman, J.; Moller, L.; Vallberg, H. Uses of indolo[2,3- b]quinoxalines. US Patent 6,465,466 B1, 2002.
47. Alphonse, F.A.; Routier, S.; Coudert, G.; Merour, J.Y. A straightforward synthesis of pyridopyrazino[2,3-b]indoles and indolo[2,3-b]quinoxalines. Heterocycles, 2001, 138, 59-75.
48. Bjorklund, U.; Engqvist, R.; Kihlstrom, I.; Gerdin, B.; Bergman, J. Alkyl substituted indoloquinoxalines. Patent WO 2005/123741, 2005.
49. Bergman, J.; Moller, L.; Vallberg, H. New uses of indolo-[2,3-b]- quinoxalines, EP0799038B1, 1998.
50. Smith, C.D.; Myers, C.B.; Zilfou, J.T.; Smith, S.N.; Lawrence, D.S. Indoloquinoxalines compounds that selectively antagonize Pglycoprotein. Oncol. Res., 2000, 12, 219-229.
51. Smith, C.D.; Myers, C.B.; Zilfou, J.T.; Smith, S.N.; Lawrence, D.S. Indoloquinoxaline compounds that selectively antagonize Pglycoprotein. Anticancer Drug Res., 2001, 12(5), 219-229.
52. Lee, B.D.; Li, Z.; French, K.J.; Zhuang, Y.; Xia, Z.; Smith, C.D. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J. Med. Chem., 2004, 47, 1413-1422.
53. Bergman J.; Engqvist R.; Gerdin, B.; Kihlstrom, I.; Bjorklund, U. Alkyl substituted indoloquinoxalines. US2005/0288296 A1, 2005 and EP1756111 B1, 2005.
54. Ueda, H.; Matsumura, Y.; Nishimura, K. Indoloquinoxaline carboxylic acid derivative or pharmacologically allowable salt thereof, and casein kinase 2 inhibitor containing the same as active component. JP2010173971, 2010.